PYPD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PolyPid Ltd (PYPD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as the FDA Fast Track designation and promising Phase 3 trial results, the company's financial performance is weak, with declining net income and EPS. Additionally, technical indicators and options data do not provide a compelling entry point for long-term investment. Holding off for further developments or financial improvement is advisable.
The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 60.824, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock's recent candlestick pattern suggests a 30% chance of declining in the short term (-2.84% in the next day, -3.37% in the next week, -3.9% in the next month). Key support and resistance levels are Pivot: 4.255, R1: 4.423, S1: 4.087, R2: 4.527, S2: 3.983.
PolyPid submitted a New Drug Application for D-PLEX₁₈₀₀ to the FDA, which has received Fast Track designation. The drug showed a 60% relative risk reduction in surgical site infections during Phase 3 trials. The company is also negotiating a U.S. commercialization partnership.
Weak financial performance with declining net income (-0.55% YoY) and EPS (-63.72% YoY). No significant hedge fund or insider trading trends. Congress trading data is unavailable. Stock trend analysis suggests a potential short-term decline.
In Q4 2025, revenue remained at 0 with no growth YoY. Net income dropped to -$8.47M (-0.55% YoY), and EPS fell to -0.41 (-63.72% YoY). Gross margin remained at 0 with no improvement.
No recent analyst ratings or price target changes are available for PYPD.
